DarioHealth (NASDAQ:DRIO – Get Rating) had its price objective cut by investment analysts at Cowen from $30.00 to $14.00 in a research report issued to clients and investors on Monday, Stock Target Advisor reports. Cowen’s price target indicates a potential upside of 152.25% from the stock’s previous close.
Other equities research analysts also recently issued reports about the company. Cowen dropped their target price on DarioHealth from $30.00 to $14.00 in a report on Monday. Aegis reduced their target price on shares of DarioHealth from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, January 26th. Finally, Alliance Global Partners lowered their price target on shares of DarioHealth from $15.50 to $11.50 in a report on Thursday, January 20th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $17.90.
Shares of DRIO traded down $0.47 during trading hours on Monday, hitting $5.55. The stock had a trading volume of 2,943 shares, compared to its average volume of 173,176. The company’s fifty day simple moving average is $6.94 and its 200 day simple moving average is $11.30. DarioHealth has a 12-month low of $5.28 and a 12-month high of $23.80. The firm has a market cap of $121.07 million, a P/E ratio of -1.33 and a beta of 1.36.
A number of hedge funds and other institutional investors have recently bought and sold shares of DRIO. Morgan Stanley grew its holdings in DarioHealth by 219.2% during the 1st quarter. Morgan Stanley now owns 3,543 shares of the company’s stock worth $68,000 after acquiring an additional 2,433 shares in the last quarter. UBS Group AG grew its position in shares of DarioHealth by 706.5% in the 3rd quarter. UBS Group AG now owns 4,250 shares of the company’s stock worth $58,000 after acquiring an additional 3,723 shares in the last quarter. Focused Wealth Management Inc boosted its holdings in DarioHealth by 150,000.0% in the fourth quarter. Focused Wealth Management Inc now owns 6,004 shares of the company’s stock worth $78,000 after purchasing an additional 6,000 shares during the period. Wells Fargo & Company MN raised its position in shares of DarioHealth by 1,498.4% during the 4th quarter. Wells Fargo & Company MN now owns 7,992 shares of the company’s stock worth $103,000 after purchasing an additional 7,492 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in DarioHealth in the third quarter worth $116,000. Hedge funds and other institutional investors own 43.10% of the company’s stock.
DarioHealth Company Profile (Get Rating)
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems.
- Get a free copy of the StockNews.com research report on DarioHealth (DRIO)
- Tapestry Stock is a Value Play Down Here
- Levi Straus Stock Ready to Buy the Dip
- Bed Bath & Beyond Stock Ready to Scale Into
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.